BashkimKadriuMD

PubMed

• Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion.
  Ruin Moaddel, Cristan A Farmer, Mani Yavi, Bashkim Kadriu, Min Zhu, Jinshui Fan, Qinghua Chen, Elin Lehrmann, Giovanna Fantoni, Supriyo De, Caio H Mazucanti, Elia E Ac...> ;Iscience. 2023 Dec 15
• 1 citations
  The impact of body mass index on the clinical features of bipolar disorder: A STEP-BD study.
  Bashkim Kadriu, Zhi-De Deng, Christoph Kraus, Jenessa N Johnston, Ioline D Henter, Siegfried Kasper, Carlos A Zarate Jr, Adam Fijtman> ;Bipolar Disorders. 2024 Mar 1
• 10 citations
  Ketamine in neuropsychiatric disorders: an update.
  Jenessa N Johnston, Bashkim Kadriu, Christoph Kraus, Ioline D Henter, Carlos A Zarate Jr> ;Neuropsychopharmacology. 2024 Jan 1
• 7 citations
  Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database.
  Christoph Kraus, Alexander Kautzky, Victoria Watzal, Anna Gramser, Bashkim Kadriu, Zhi-De Deng, Lucie Bartova, Carlos A Zarate Jr, Rupert Lanzenberger, Daniel Souery, ...> ;Journal of Affective Disorders. 2023 Aug 15
• 3 citations
  Consistency checks to improve measurement with the Hamilton Rating Scale for Anxiety (HAM-A).
  Jonathan Rabinowitz, Janet B W Williams, Nanco Hefting, Ariana Anderson, Brianne Brown, Dong Jing Fu, Bashkim Kadriu, Alan Kott, Atul Mahableshwarkar, Jan Sedway, Davi...> ;Journal of Affective Disorders. 2023 Mar 15
• 12 citations
  Inflammation, stress and depression: An exploration of ketamine's therapeutic profile.
  Jenessa N Johnston, Maximillian S Greenwald, Ioline D Henter, Christoph Kraus, Anahit Mkrtchian, Neil G Clark, Lawrence T Park, Philip Gold, Carlos A Zarate Jr, Bashki...> ;Drug Discovery Today. 2023 Apr 1
• 17 citations
  Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
  Jenessa N Johnston, Bashkim Kadriu, Josh Allen, Jessica R Gilbert, Ioline D Henter, Carlos A Zarate Jr> ;Neuropharmacology. 2023 Mar 15
• 8 citations
  Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.
  Ruin Moaddel, Panos Zanos, Cristan A Farmer, Bashkim Kadriu, Patrick J Morris, Jacqueline Lovett, Elia E Acevedo-Diaz, Grace W Cavanaugh, Peixiong Yuan, Mani Yavi, Cra...> ;Translational Psychiatry. 2022 May 2
• 6 citations
  Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D).
  Jonathan Rabinowitz, Janet B W Williams, Ariana Anderson, Dong Jing Fu, Nanco Hefting, Bashkim Kadriu, Alan Kott, Atul Mahableshwarkar, Jan Sedway, David Williamson, C...> ;Journal of Affective Disorders. 2022 Apr 1
• 1 citations
  Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
  Marina Kojic, Johan Saelens, Bashkim Kadriu, Carlos A Zarate Jr, Christoph Kraus> ;Current Topics in Behavioral Neurosciences. 2022 Jan 1
• 26 citations
  Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.
  Bashkim Kadriu, Laura Musazzi, Jenessa N. Johnston, Lisa E. Kalynchuk, Hector J. Caruncho, Maurizio Popoli, Carlos A. Zarate> ;Drug Discovery Today. 2021 Aug 3
• Reply to: "Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of ...
  Elia E. Acevedo-Diaz, Maximillian Greenwald, Grace W. Cavanaugh, Dede Greenstein, Christoph Kraus, Bashkim Kadriu, Carlos A. Zarate, Lawrence Park> ;Journal of Psychiatric Research. 2021 Mar 16
• 15 citations
  Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor.
  Dede Greenstein, Bashkim Kadriu, Peixiong Yuan, Lawrence Park, Todd D. Gould, Carlos A. Zarate> ;Journal of Affective Disorders. 2021 Feb 1
• 48 citations
  Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.
  Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, Jessica R. Gilbert, Christoph Kraus, Lawrence Park, Carlos A. Zarate> ;The International Journal of Neuropsychopharmacology. 2021 Jan 20
• 16 citations
  Can ‘floating’ predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression
  Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, Christoph Kraus, Bashkim Kadriu, Lawrence Park, Carlos A. Zarate> ;Journal of Psychiatric Research. 2020 Nov 1
• 15 citations
  The effects of ketamine on typical and atypical depressive symptoms.
  Lawrence Park, David A. Luckenbaugh, S. J. Pennybaker, Matthew Hopkins, Ioline D. Henter, Marc S. Lener, Bashkim Kadriu, Elizabeth D. Ballard, Carlos A. Zarate> ;Acta Psychiatrica Scandinavica. 2020 Nov 1
• 49 citations
  Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.
  Anahit Mkrtchian, Jennifer W. Evans, Christoph Kraus, Peixiong Yuan, Bashkim Kadriu, Allison C. Nugent, Jonathan P. Roiser, Carlos A. Zarate> ;Molecular Psychiatry. 2021 Jul 1
• 39 citations
  A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression.
  Lawrence Park, Bashkim Kadriu, Todd D. Gould, Panos Zanos, Deanna Greenstein, Jennifer W. Evans, Peixiong Yuan, Cristan Farmer, Mark Oppenheimer, Jomy M. George, Lilia...> ;The International Journal of Neuropsychopharmacology. 2020 Jul 29
• 33 citations
  Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
  Cristan A Farmer, Jessica R Gilbert, Ruin Moaddel, Jomy George, Lilian Adeojo, Jacqueline Lovett, Allison C Nugent, Bashkim Kadriu, Peixiong Yuan, Todd D Gould, Lawren...> ;Neuropsychopharmacology. 2020 Jul 1
• 1 citations
  Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
  Cristan A Farmer, Jessica R Gilbert, Ruin Moaddel, Jomy George, Lilian Adeojo, Jacqueline Lovett, Allison C Nugent, Bashkim Kadriu, Peixiong Yuan, Todd D Gould, Lawren...> ;Neuropsychopharmacology. 2020 Jul 1
• 19 citations
  Neurobiological biomarkers of response to ketamine
  Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus, Carlos A. Zarate> ;Advances in Pharmacology. 2020 Jun 18
• 5 citations
  Not So Fast: Recent Successes and Failures in Treating Depression.
  Bashkim Kadriu, Zhi-De Deng, Christoph Kraus, Ioline D. Henter, Sarah H. Lisanby, Carlos A. Zarate> ;The Journal of Clinical Psychiatry. 2020 May 26
• 13 citations
  Prognosis and Improved Outcomes in Major Depression: A Review.
  Christoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, Carlos A. Zarate, Siegfried Kasper> ;Focus. 2020 Apr 24
• 55 citations
  Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
  Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, Christoph Kraus, Bashkim Kadriu, Carlos A. Zarate, Lawrence Park> ;Journal of Affective Disorders. 2020 Feb 15
• 32 citations
  Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment.
  Christoph Kraus, Anahit Mkrtchian, Bashkim Kadriu, Allison C. Nugent, Carlos A. Zarate, Jennifer W. Evans> ;Neuropsychopharmacology. 2020 Jan 29
• Join now to see all